DENTSPLY SIRONA Inc. (XRAY) Stock Analysis

Q: What is the XRAY stock price target?

Take-profit $12.24 (+24.6% upside). Prior stop was $9.52.

Q: Is XRAY overvalued or undervalued?

DENTSPLY SIRONA Inc. trades at a P/E of N/A (forward 6.4). TrendMatrix value score: 8.7/10. Overall verdict: Sell.

Q: What do analysts say about XRAY?

22 analysts cover XRAY with a consensus score of 3.4/5. Average price target: $14.

Q: What does DENTSPLY SIRONA Inc. do?

Dentsply Sirona is the largest diversified manufacturer of professional dental products and technologies, selling into approximately 140 countries through Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare segments. Revenue comes from equipment, consumables, software, and continence care products; Henry Schein accounted for 13% of 2025 net sales.

Falling Knife setup

SellModerate ConfidenceUpdated 1 days ago (May 19, 2026, 9:16 AM ET)

Healthcare · Medical Instruments & Supplies

Sell if holding. Engine safety override at $9.82: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 2.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality; Negative price momentum.

$9.82+24.6% A.UpsideScore 4.8/10#21 of 25 Medical Instruments & Supplies

QualityF-score8 / 9FCF yield6.59%

IncomeYield5.04%(5y avg 2.34%)Payout28.83%sustainable

Stop $9.52Target $12.24(analyst − 10%)A.R:R 2.5:1

Analyst target$13.60+38.5%15 analysts

$12.24our TP

$9.82price

$13.60mean

$17

Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.

Recent Developments — DENTSPLY SIRONA Inc.

Latest news

Mizuho Maintains Neutral on Dentsply Sirona, Lowers Price Target to $14 — benzinga May 6, 2026 negative
Dentsply Sirona Q1 2026 Earnings Call Transcript — benzinga May 5, 2026 neutral
Dentsply Sirona Affirms FY2026 Adj EPS Guidance of $1.40-$1.50 vs $1.43 Est; Affirms FY2026 Sales Guidance of $3.500B-$3 — benzinga May 5, 2026 neutral
Dentsply Sirona Q1 Adj. EPS $0.27 Misses $0.28 Estimate, Sales $880.000M Beat $842.589M Estimate — benzinga May 5, 2026 neutral
Earnings Scheduled For May 5, 2026 — benzinga May 5, 2026 neutral

Generated 2026-05-20T20:21:22Z.

Thesis

Rewards

No bull case signals

Risks

Quality below floor (3.5 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)6.4

Mkt Cap$2.0B

EV/EBITDA7.4

Profit Mgn-17.1%

ROE-37.7%

Rev Growth0.1%

Beta0.94

Dividend5.04%

Rating analysts22

Quality Signals

Piotroski F8/9

Options Flow

P/C0.29bullish

IV78%elevated

Max Pain$3-74.5% vs spot

Concentration Risks(10-K Item 1A)

LOWCustomerHenry Schein, Inc.13%
10-K Item 1: 'Henry Schein, Inc. ... 13 | %'

Material Events(8-K, last 90d)

2026-02-24Item 5.02LOW
Board increased from 11 to 13 directors; James D. Forbes and Brian P. McKeon appointed effective February 27, 2026. Forbes to Compensation & Human Capital Committee; McKeon to Audit/Finance and Science & Technology Committees. Routine board expansion; no officer departures.
SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

4 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value8.715%1.30

Quality3.515%0.53

Growth2.515%0.38

Momentum2.010%0.20

Sentiment6.010%0.60

Insider Activity6.510%0.65

Peer Rank4.010%0.40

Technical Setup6.75%0.34

Risk Profile4.05%0.20

Catalyst3.35%0.17

Overall (Σ contributions)4.76

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd

0.9

Obv

1.0

Ma Position

1.0

Rsi

3.0

Volume

3.9

Capitulation risk (RSI 20, below 200MA)Volume distribution (falling OBV)Below 200-MA, MA slope -4.7%/30d — confirmed downtrend

Growth below the gate floor. Component breakdown shows what dragged the score down.static

Revenue Growth

2.5

Low model confidence on this dimension (33%).

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Surprise Avg

0.0

Earnings History

1.1

Erm

3.5

Earnings Timing

5.0

Dividend Safety

7.0

Earnings concerns: 1B/2MDividend: 504.0%

Unprofitable operations — net margin -17.1%. Quality floor flags this regardless of sector context.static

Roe

0.0

Net Margin

0.0

Operating Margin

1.4

Roa

1.5

Moat

3.9

Fcf Quality

4.7

Current Ratio

5.6

Gross Margin

5.8

Piotroski F

8.9

FCF-positive but moderate margins (FCF margin 4%, FCF yield 6.6%)No competitive moatStrong Piotroski F-Score: 8/9

GatesMomentum 2.0<4.5Death cross (50MA < 200MA)A.R:R 2.5 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 79d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARFalling KnifeSuitability: Aggressive

RSI

20 · Oversold

↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $9.81Resistance $13.01

Price Targets

$10

$12

A.Upside+24.6%

A.R:R2.5:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (3.5 < 4.0)

! Momentum score 2.0/10 — below 4.5 minimum

! Death cross — 50-day MA below 200-day MA

Earnings

1/4 beats

Next Earnings2026-08-06 (79d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is XRAY stock a buy right now?

Sell if holding. Engine safety override at $9.82: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 2.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality; Negative price momentum. Chart setup: Death cross, below all MAs, RSI 20, MACD bearish. Prior stop was $9.52. Score 4.8/10, moderate confidence.

What is the XRAY stock price target?

Take-profit target: $12.24 (+24.6% upside). Prior stop was $9.52. Stop-loss: $9.52.

What are the risks of investing in XRAY?

Quality below floor (3.5 < 4.0).

Is XRAY overvalued or undervalued?

DENTSPLY SIRONA Inc. trades at a P/E of N/A (forward 6.4). TrendMatrix value score: 8.7/10. Verdict: Sell.

What do analysts say about XRAY?

22 analysts cover XRAY with a consensus score of 3.4/5. Average price target: $14.

What does DENTSPLY SIRONA Inc. do?Dentsply Sirona is the largest diversified manufacturer of professional dental products and technologies, selling into...

Dentsply Sirona is the largest diversified manufacturer of professional dental products and technologies, selling into approximately 140 countries through Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare segments. Revenue comes from equipment, consumables, software, and continence care products; Henry Schein accounted for 13% of 2025 net sales.